Back to Directory
Last Updated: 07/05/2026

Amicus Therapeutics

South East England
Founded 2002
UK commercial base for a rare metabolic disease biotech

Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases.

The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease.

The UK office in Marlow serves as the commercial and medical affairs base for Great Britain and Ireland.

BiopharmaDrug DiscoveryImmunologyCell & Gene Therapy
Rare DiseasesMetabolic Disease

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of